BREAKING NEWS
Study Estimates Health Risks for Women Exposed to DES In Utero
Up until 1971, doctors in the United States prescribed a drug called diethylstilbestrol (DES) to millions of healthy pregnant women. The daughters of these women, who were exposed to the drug in utero, are at an increased risk of developing a range of adverse health effects related to the exposure. A study in the October 6 New England Journal of Medicine estimates the absolute risks of these health effects and summarizes decades of research on so-called DES daughters. For more information, see NCI's press release.
NEWS
Combination Therapy May Help Some Patients with Advanced Breast Cancer
A combination of two available cancer drugs could offer a new treatment option for postmenopausal women whose advanced breast cancer has stopped responding to hormonal therapy, researchers said last week at a scientific meeting in Stockholm, Sweden.
Read more > >
Rising Oropharyngeal Cancer Rates Linked to HPV Infection
Disease may become the most common HPV-associated cancers by 2020Hospitalization Following Prostate Biopsy Common in Older Men
Hospitalizations for bacterial infections may be linked to antibiotic-resistant strainsStudy Examines Sex Differences in Screening Colonoscopy Findings
Research in Austria shows differences, but results may not apply to the U.S. populationDelivering Chemotherapy to the Liver May Benefit Patients with Metastatic Melanoma
A new technique delays disease progression while offering good quality of lifeSmoking Cessation Drug Proves Effective in Single-Center Trial
Cytisine also costs less than other smoking cessation treatmentsAlso in the Journals: Zoleodronic Acid May Benefit Postmenopausal Women with Breast Cancer
COMMENTARY
NCI's Office of Advocacy Relations: Bringing Advocacy and Research Together
by Shannon Bell
Just as researchers and clinicians have begun to better understand that cancer is a highly complex group of diseases and have adjusted how they study and treat these diseases, cancer advocates have realized that effective advocacy is a complex and multidimensional pursuit—one in which they can play many roles. Read more > >
A Conversation with Dr. Jane Perlmutter about the Role of Advocates in Cancer Research
A breast cancer survivor and cancer research advocate explains why she turned to advocacy and describes her experience as the lead advocate on one national study. Read more > >
IN DEPTH
Workshop Examines Causes, Potential Remedies for Drug Shortages
Cancer care and clinical trials are affected, participants say
Changing Face of Cancer in HIV-Positive Patients Requires New Approaches to Clinical Trials
Inclusion of more HIV-positive patients in cancer trials needed to improve care
Featured Clinical Trial: Testing Adjuvant Ipilimumab in Advanced Melanoma
Will giving ipilimumab after surgery delay recurrence and improve survival when compared to interferon alfa-2b?
NCI Director's Consumer Liaison Group Focuses on Improving Clinical Trials
The group met recently to discuss advocates' roles in the clinical trials process
UPDATES
FDA Update
- Bone Density Drug Approved for Prostate and Breast Cancer Patients
NIH Update
- NIH's Intramural Research Program Unveils New Website
Legislative Update
- Congressional Members and Staff Turn to NCI for Cancer Research Information
- Congressional Appropriations Committees Put Forward Labor-HHS Bills
Cancer.gov Update
- NCI Updates Online Dietary Recall Tool
Notes
- Rudolf Jaenisch Receives National Medal of Science
- NCI's James Gulley Wins Presidential Early Career Award for Scientists and Engineers
- New National Cancer Advisory Board Member Named
- Cyber-Seminar Will Address Cancer Control and Prevention for Latino Populations
- Small Businesses: Apply for Cancer Research Funding by November 7
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit .
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
